Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26192078 | 1.00 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL24702744 | 1.00 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL26192479 | 1.00 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL24702743 | 1.00 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713675 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL24004406 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL23266290 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713626 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20713629 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL17703268 | 0.98 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131867-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | SLOAN KETTERING INST CANCER RES (US) | 2023-04-27 | — | — | US | disclosed |
| US-20170283450-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | MEMORIAL SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131867-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | LSS, CYP51A1, TLR7 | L3MBTL1 2235/4885MAPT 4111/4885POLB 826/4885 |
| US-20170283450-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | LSS, CYP51A1, TLR7 | L3MBTL1 2235/4885MAPT 4111/4885POLB 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.